Unleashing Natural IL18 Activity Using an Anti-IL18BP Blocker Induces Potent Immune Stimulation and Antitumor Effects.

Autor: Menachem A; Preclinical Development, Compugen Ltd., Holon, Israel., Alteber Z; Research & Drug Discovery, Compugen Ltd., Holon, Israel., Cojocaru G; Computational Discovery, Compugen Ltd., Holon, Israel., Fridman Kfir T; Research & Drug Discovery, Compugen Ltd., Holon, Israel., Blat D; Research & Drug Discovery, Compugen Ltd., Holon, Israel., Leiderman O; Research & Drug Discovery, Compugen Ltd., Holon, Israel., Galperin M; Research & Drug Discovery, Compugen Ltd., Holon, Israel., Sever L; Research & Drug Discovery, Compugen Ltd., Holon, Israel., Cohen N; Research & Drug Discovery, Compugen Ltd., Holon, Israel., Cohen K; Research & Drug Discovery, Compugen Ltd., Holon, Israel., Granit RZ; Computational Discovery, Compugen Ltd., Holon, Israel., Vols S; Computational Discovery, Compugen Ltd., Holon, Israel., Frenkel M; Research & Drug Discovery, Compugen Ltd., Holon, Israel., Soffer L; Research & Drug Discovery, Compugen Ltd., Holon, Israel., Meyer K; Research & Drug Discovery, Compugen Ltd., Holon, Israel., Menachem K; Research & Drug Discovery, Compugen Ltd., Holon, Israel., Galon Tilleman H; Research & Drug Discovery, Compugen Ltd., Holon, Israel., Morein D; Research & Drug Discovery, Compugen Ltd., Holon, Israel., Borukhov I; Computational Discovery, Compugen Ltd., Holon, Israel., Toporik A; Computational Discovery, Compugen Ltd., Holon, Israel., Perpinial Shahor M; Research & Drug Discovery, Compugen Ltd., Holon, Israel., Tatirovsky E; Research & Drug Discovery, Compugen Ltd., Holon, Israel., Mizrachi A; Department of Otolaryngology Head and Neck Surgery, Rabin Medical Center, Petah Tikva, Israel.; Faculty of Medicine, Tel Aviv University, Tel Aviv-Yafo, Israel., Levy-Barda A; Biobank, Department of pathology, Rabin Medical Center, Petah Tikva, Israel., Sadot E; Faculty of Medicine, Tel Aviv University, Tel Aviv-Yafo, Israel.; Department of Surgery, Rabin Medical Center, Petach Tikva, Israel., Strenov Y; Faculty of Medicine, Tel Aviv University, Tel Aviv-Yafo, Israel.; Department of Pathology, Rabin Medical Center, Petah Tikva, Israel., Eitan R; Faculty of Medicine, Tel Aviv University, Tel Aviv-Yafo, Israel.; Gynecologic Oncology Division, Helen Schneider Hospital for Women, Rabin Medical Center, Petah Tikva, Israel., Jakobson-Setton A; Faculty of Medicine, Tel Aviv University, Tel Aviv-Yafo, Israel.; Gynecologic Oncology Division, Helen Schneider Hospital for Women, Rabin Medical Center, Petah Tikva, Israel., Yanichkin N; Department of Pathology, Rabin Medical Center, Petah Tikva, Israel., Ferre P; Preclinical Development, Compugen Ltd., Toulouse, France., Ophir E; Compugen Ltd., Holon, Israel.

Publikováno v: Cancer immunology research [Cancer Immunol Res] 2024 Jun 04; Vol. 12 (6), pp. 687-703.

LEAP2 Is an Endogenous Antagonist of the Ghrelin Receptor.

Autor: Ge X; NGM Biopharmaceuticals, South San Francisco, CA 94080, USA. Electronic address: xge2@ucmerced.edu., Yang H; NGM Biopharmaceuticals, South San Francisco, CA 94080, USA., Bednarek MA; Department of Antibody Discovery & Protein Engineering, MedImmune Ltd, Cambridge CB21 6GH, UK., Galon-Tilleman H; NGM Biopharmaceuticals, South San Francisco, CA 94080, USA., Chen P; NGM Biopharmaceuticals, South San Francisco, CA 94080, USA., Chen M; NGM Biopharmaceuticals, South San Francisco, CA 94080, USA., Lichtman JS; NGM Biopharmaceuticals, South San Francisco, CA 94080, USA., Wang Y; NGM Biopharmaceuticals, South San Francisco, CA 94080, USA., Dalmas O; NGM Biopharmaceuticals, South San Francisco, CA 94080, USA., Yin Y; NGM Biopharmaceuticals, South San Francisco, CA 94080, USA., Tian H; NGM Biopharmaceuticals, South San Francisco, CA 94080, USA., Jermutus L; Department of Antibody Discovery & Protein Engineering, MedImmune Ltd, Cambridge CB21 6GH, UK; Department of Cardiovascular and Metabolic Disease Research, MedImmune LLC, Gaithersburg, MD 20878, USA., Grimsby J; Department of Cardiovascular and Metabolic Disease Research, MedImmune LLC, Gaithersburg, MD 20878, USA., Rondinone CM; Department of Cardiovascular and Metabolic Disease Research, MedImmune LLC, Gaithersburg, MD 20878, USA., Konkar A; Department of Cardiovascular and Metabolic Disease Research, MedImmune LLC, Gaithersburg, MD 20878, USA., Kaplan DD; NGM Biopharmaceuticals, South San Francisco, CA 94080, USA. Electronic address: dkaplan@ngmbio.com.

Publikováno v: Cell metabolism [Cell Metab] 2018 Feb 06; Vol. 27 (2), pp. 461-469.e6. Date of Electronic Publication: 2017 Dec 07.

Apelin-36 Modulates Blood Glucose and Body Weight Independently of Canonical APJ Receptor Signaling.

Autor: Galon-Tilleman H; From NGM Biopharmaceuticals, South San Francisco, California 94080., Yang H; From NGM Biopharmaceuticals, South San Francisco, California 94080., Bednarek MA; the Department of Antibody Discovery and Protein Engineering, MedImmune Ltd., Cambridge CB21 6GH, United Kingdom., Spurlock SM; From NGM Biopharmaceuticals, South San Francisco, California 94080., Paavola KJ; From NGM Biopharmaceuticals, South San Francisco, California 94080., Ko B; From NGM Biopharmaceuticals, South San Francisco, California 94080., To C; From NGM Biopharmaceuticals, South San Francisco, California 94080., Luo J; From NGM Biopharmaceuticals, South San Francisco, California 94080., Tian H; From NGM Biopharmaceuticals, South San Francisco, California 94080., Jermutus L; the Department of Antibody Discovery and Protein Engineering, MedImmune Ltd., Cambridge CB21 6GH, United Kingdom., Grimsby J; the Department of Cardiovascular and Metabolic Disease Research, MedImmune LLC, Gaithersburg, Maryland 20878., Rondinone CM; the Department of Cardiovascular and Metabolic Disease Research, MedImmune LLC, Gaithersburg, Maryland 20878., Konkar A; the Department of Cardiovascular and Metabolic Disease Research, MedImmune LLC, Gaithersburg, Maryland 20878., Kaplan DD; From NGM Biopharmaceuticals, South San Francisco, California 94080. Electronic address: dkaplan@ngmbio.com.

Publikováno v: The Journal of biological chemistry [J Biol Chem] 2017 Feb 03; Vol. 292 (5), pp. 1925-1933. Date of Electronic Publication: 2016 Dec 19.

The GHSR1a antagonist LEAP2 regulates islet hormone release in a sex-specific manner.

Autor: Hewawasam, Nirun, Sarkar, Debalina, Bolton, Olivia, Delishaj, Blerinda, Almutairi, Maha, King, Aileen J. F., Dereli, Ayse S., Despontin, Chloe, Gilon, Patrick, Reeves, Sue, Patterson, Michael, Hauge-Evans, Astrid C.

Publikováno v: Journal of Endocrinology; Nov2024, Vol. 263 Issue 2, p1-14, 14p

LEAP2, a ghrelin receptor inverse agonist, and its effect on alcohol-related responses in rodents.

Autor: Tufvesson-Alm, Maximilian, Aranäs, Cajsa, Blid Sköldheden, Sebastian, Vestlund, Jesper, Edvardsson, Christian E., Jerlhag, Elisabet

Publikováno v: Translational Psychiatry; 10/2/2024, Vol. 14 Issue 1, p1-9, 9p